SEC Filing Summary: Angion Biomedica Corp. (ANGN)
Business Context and Reporting Period
This Form 8-K was filed by Angion Biomedica Corp. on October 26, 2021. The registrant is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol ANGN. The report addresses Item 2.02 regarding Results of Operations and Financial Condition.
Key Financial Metrics
The filing provides a specific liquidity update regarding the company's cash position as of September 30, 2021.
- Cash and Cash Equivalents: Approximately $100 million (as of September 30, 2021).
- Revenue, Profit, Margins, and Debt: The filing text does not provide clear values for these metrics.
Material Changes
The filing does not explicitly detail material changes compared to prior periods, other than the confirmation of the cash balance level expected to be reported in the upcoming quarterly earnings.
Guidance, Outlook, and Management Commentary
Management announced that the company expects to report the aforementioned cash balance when it releases its quarterly earnings in November 2021. No specific forward-looking guidance regarding revenue, product development milestones, or operational risks was included in this specific text.
Investor Verification Checklist
- Verify the exact cash and cash equivalents figure in the official Q3 2021 earnings release scheduled for November 2021.
- Review the full quarterly report for details on operating expenses, net loss, and cash burn rate, which are not included in this 8-K.
- Confirm the company's status as an emerging growth company and any related accounting election impacts.